TWiV 1062: Clinical update with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Coverage with selected vaccines and exemption from school vaccine requirements among (CDC)
- Seasonality of endemic COVID-19 (Virology)
- mRNA SARS-CoV-2 vaccination before vs during pregnancy and Omicron infection among infants (JAMA)
- Extracting symptoms from responses using ChatGPT among COVID-19 cases (CMI)
- SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
- Optimization of antiviral therapy in immunocompromised COVID-19 patients (ClinicalTrials)
- A study to learn about nirmatrelvir/ritonavir in people with COVID-19 and a compromised immune system (ClinicalTrials)
- Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection (EJP)
- Effect of neutralizing monoclonal antibody treatment on virologic and immunologic biomarkers in patients with COVID-19 (JID)
- SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy (AIM)
- Contribute to our MicrobeTV fundraiser at PWB
- Letters read on TWiV on TWiV 1062
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]